Tanta Medical Journal

ORIGINAL ARTICLE
Year
: 2017  |  Volume : 45  |  Issue : 3  |  Page : 129--134

Bortezomib in multiple myeloma: treatment response and survival outcome


Eslam S.M Bassiony, Ashraf F Barakat, Amr A.E Ghannam, Essam A Abozena 
 Clinical Oncology and Nuclear Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt

Correspondence Address:
Eslam S.M Bassiony
Clinical Oncology, Faculty of Medicine, Tanta University, Tanta, 31511
Egypt

Background Bortezomib, a first-in-class proteasome inhibitor, was approved by the Food and Drug Administration in 2003. Bortezomib has come a long way since its development as one of the most effective drugs currently available for treating multiple myeloma. With improved efficacy of combination regimens, we have seen increasing use of its therapeutic spectrum ranging from frontline induction to maintenance therapy. Bortezomib has been integrated into the treatment of myeloma at every disease stage. Aim The aim of this study was to evaluate the disease response and survival outcome in patients with multiple myeloma who were treated with bortezomib as first-line or second-line treatment who had recurrent or refractory disease after systemic chemotherapy. Patients and methods This retrospective study included 23 patients with multiple myeloma who were treated at Clinical Oncology and Nuclear Medicine Department, Tanta University Hospital, Faculty of Medicine, Tanta University, and were diagnosed between January 2012 and January 2016. Nine patients received bortezomib as a first-line treatment, whereas 14 patients received it as a second-line treatment. Results Bortezomib shows better response rate and survival outcome especially in patients who received it as the first line of treatment. About 52.5% of patients show partial response or better response. Conclusion Bortezomib with dexamethasone gives a response rate and survival outcome better than conventional treatment, dexamethasone alone, or bortezomib single agent. However, bortezomib combination with other chemotherapeutic agents gives more response rate than bortezomib with dexamethasone.


How to cite this article:
Bassiony ES, Barakat AF, Ghannam AA, Abozena EA. Bortezomib in multiple myeloma: treatment response and survival outcome.Tanta Med J 2017;45:129-134


How to cite this URL:
Bassiony ES, Barakat AF, Ghannam AA, Abozena EA. Bortezomib in multiple myeloma: treatment response and survival outcome. Tanta Med J [serial online] 2017 [cited 2018 Aug 17 ];45:129-134
Available from: http://www.tdj.eg.net/article.asp?issn=1110-1415;year=2017;volume=45;issue=3;spage=129;epage=134;aulast=Bassiony;type=0